ArticlePloS one2014
Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 90 citations in OpenAlex.
- Article
- Autofluorescence and deep learning in early disease detection: biological foundations, clinical applications, and future directions.Frontiers in artificial intelligence · 2026Review
- Fluorescence Lifetime Imaging Techniques-A Review on Principles, Applications and Clinical Relevance.Journal of biophotonics · 2025Review
- Temozolomide-induced senescent glioblastoma cells acquire sensitivity to TRAIL death receptor 5-mediated apoptosis.Medical oncology (Northwood, London, England) · 2025Article
- Differentiation of Tumors of the Upper Respiratory Tract Using Optical Metabolic Imaging.Lasers in surgery and medicine · 2025Article
- Optical imaging provides flow-cytometry-like single-cell level analysis of HIF-1Biophotonics discovery · 2025Article
- Efficacy Evaluation of "Enhanced" Natural Killers withSovremennye tekhnologii v meditsine · 2025Article
- Quantifying Spatiotemporal Heterogeneity of Tumor Metabolism and Vasculature with a Multiparametric Point-of-Investigation Microscope.BME frontiers · 2025Article
- Phasor-FLIM and SHG imaging for quantitative analysis of lung cancer autofluorescence.Computational and structural biotechnology journal · 2025Article
- Article
- Quantitative Optical Redox Imaging of Melanoma Xenografts with Different Metastatic Potentials.Cancers · 2024Article
- 3D convolutional neural networks predict cellular metabolic pathway use from fluorescence lifetime decay data.APL bioengineering · 2024Article
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Portable optical spectroscopic assay for non-destructive measurement of key metabolic parameters onBiomedical optics express · 2023Article
- Light-sheet autofluorescence lifetime imaging with a single-photon avalanche diode array.Journal of biomedical optics · 2023Article
- Measurement of Patient-Derived Glioblastoma Cell Response to Temozolomide Using Fluorescence Lifetime Imaging of NAD(P)H.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Light sheet autofluorescence lifetime imaging with a single photon avalanche diode array.bioRxiv : the preprint server for biology · 2023Article
- Aligning Small Datasets Using Domain Adversarial Learning: Applications in Automated in Vivo Oral Cancer Diagnosis.IEEE journal of biomedical and health informatics · 2023Article
- Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.The Prostate · 2022Article
- Single cell metabolism: current and future trends.Metabolomics : Official journal of the Metabolomic Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Optical metabolic imaging measures fluorescence intensity and lifetimes from metabolic cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). These molecular level measurements provide unique biomarkers for early cellular responses to cancer treatments. Head and neck squamous cell carcinoma (HNSCC) is an attractive target for optical imaging because of easy access to the site using fiber optic probes. Two HNSCC cell lines, SCC25 and SCC61, were treated with Cetuximab (anti-EGFR antibody), BGT226 (PI3K/mTOR inhibitor), or cisplatin (chemotherapy) for 24 hours. Results show increased redox ratio, NADH α1 (contribution from free NADH), and FAD α1 (contribution from protein-bound FAD) for malignant cells compared with the nonmalignant cell line OKF6 (p<0.05). In SCC25 and SCC61 cells, the redox ratio is unaffected by cetuximab treatment and decreases with BGT226 and cisplatin treatment (p<0.05), and these results agree with standard measurements of proliferation rates after treatment. For SCC25, NADH α1 is reduced with BGT226 and cisplatin treatment. For SCC61, NADH α1 is reduced with cetuximab, BGT226, and cisplatin treatment. Trends in NADH α1 are statistically similar to changes in standard measurements of glycolytic rates after treatment. FAD α1 is reduced with cisplatin treatment (p<0.05). These shifts in optical endpoints reflect early metabolic changes induced by drug treatment. Overall, these results indicate that optical metabolic imaging has potential to detect early response to cancer treatment in HNSCC, enabling optimal treatment regimens and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.